D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

Luis Schwarzstein; Néstor J. Aparicio; Andrew V. Schally

doi:10.1111/j.1365-2605.1982.tb00244.x

D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

Luis Schwarzstein, Néstor J. Aparicio, Andrew V. Schally

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

Original language	English (US)
Pages (from-to)	171-178
Number of pages	8
Journal	International Journal of Andrology
Volume	5
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2605.1982.tb00244.x
State	Published - Apr 1982
Externally published	Yes

Keywords

LH‐RH agonists
oligoasthenozoospermia treatment

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Reproductive Medicine
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2605.1982.tb00244.x

Cite this

@article{ae2a894941ff425dba536e7d75a6b368,

title = "D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia",

abstract = "D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.",

keywords = "LH‐RH agonists, oligoasthenozoospermia treatment",

author = "Luis Schwarzstein and Aparicio, {N{\'e}stor J.} and Schally, {Andrew V.}",

year = "1982",

month = apr,

doi = "10.1111/j.1365-2605.1982.tb00244.x",

language = "English (US)",

volume = "5",

pages = "171--178",

journal = "International Journal of Andrology",

issn = "0105-6263",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

AU - Schwarzstein, Luis

AU - Aparicio, Néstor J.

AU - Schally, Andrew V.

PY - 1982/4

Y1 - 1982/4

N2 - D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

AB - D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

KW - LH‐RH agonists

KW - oligoasthenozoospermia treatment

UR - http://www.scopus.com/inward/record.url?scp=0020081008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020081008&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2605.1982.tb00244.x

DO - 10.1111/j.1365-2605.1982.tb00244.x

M3 - Article

C2 - 6213567

AN - SCOPUS:0020081008

VL - 5

SP - 171

EP - 178

JO - International Journal of Andrology

JF - International Journal of Andrology

SN - 0105-6263

IS - 2

ER -

D‐Tryptophan‐6‐luteinizing hormone‐releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this